Skoči na glavni sadržaj

Recenzija, Prikaz slučaja

https://doi.org/10.20471/acc.2020.59.04.25

Oxaliplatin Induced Pulmonary Fibrosis: a Case Report

Mirjana Pavlović orcid id orcid.org/0000-0002-9633-064X ; Sestre milosrdnice University Hospital Centre, University Hospital for Tumors, Department of Medical Oncology, Zagreb, Croatia
Robert Šeparović orcid id orcid.org/0000-0002-4002-2699 ; Sestre milosrdnice University Hospital Centre, University Hospital for Tumors, Department of Medical Oncology, Zagreb, Croatia
Tajana Silovski orcid id orcid.org/0000-0002-4699-5432 ; Sestre milosrdnice University Hospital Centre, University Hospital for Tumors, Department of Medical Oncology, Zagreb, Croatia
Ana Tečić Vuger orcid id orcid.org/0000-0003-2203-161X ; Sestre milosrdnice University Hospital Centre, University Hospital for Tumors, Department of Medical Oncology, Zagreb, Croatia
Andreja Jurić orcid id orcid.org/0000-0002-7539-2278 ; Sestre milosrdnice University Hospital Centre, University Hospital for Tumors, Department of Medical Oncology, Zagreb, Croatia


Puni tekst: engleski pdf 371 Kb

str. 761-764

preuzimanja: 633

citiraj


Sažetak

Oxaliplatin is part of the standard chemotherapy regimens for treating colorectal
carcinoma. Pulmonary fibrosis is a serious but rare side effect of oxaliplatin treatment, which resulted
in patient death in more than half of the reported cases. The precise pathophysiological mechanism of
this phenomenon has not been clarified yet. Analysis of the reported cases strongly suggests that
early diagnosis and immediate corticosteroid treatment are crucial for better prognosis. Here we report
a case of pulmonary fibrosis related to the FOLFOX regimen in a patient with early colorectal
carcinoma.

Ključne riječi

Oxaliplatin; Colon cancer; Side effects; Pulmonary fibrosis; Interstitial lung disease

Hrčak ID:

255233

URI

https://hrcak.srce.hr/255233

Datum izdavanja:

1.12.2020.

Podaci na drugim jezicima: hrvatski

Posjeta: 2.274 *